An approach to therapy for paroxysmal supraventricular tachycardia
Identifieur interne : 000153 ( Istex/Corpus ); précédent : 000152; suivant : 000154An approach to therapy for paroxysmal supraventricular tachycardia
Auteurs : George J. Klein ; Arjun D. Sharma ; Raymond YeeSource :
- The American Journal of Cardiology [ 0002-9149 ] ; 1987.
Abstract
A variety of options are available for managing recurrent paroxysmal supraventricular tachycardia. These options include empirical drug therapy on a trial and error basis, drug therapy based on the results of electrophysiologic testing and nonpharmacologic treatment including operative therapy, catheter ablation and antitachycardia devices. Empirical drug therapy is appropriate when the tachycardia is relatively well tolerated and the patient has access to a medical facility. Therapy guided by electrophysiologic testing is more appropriate for patients with severe symptoms during tachycardia, patients with a potential for more serious arrhythmias such as atrial fibrillation in the Wolff-Parkinson-White syndrome and in patients who have failed to respond to empirical trials of drug therapy. Electrophysiologic testing usually provides information about the precise mechanism responsible for the tachycardia and allows verification of drug efficacy. It is a strict prerequisite for operative, ablative or antitachycardia device therapy. The choice of therapy depends a great deal on local expertise, patient preference and individual considerations. Operative therapy is very successful in patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome and should be given high priority as an option in younger patients facing a lifelong commitment to antiarrhythmic drugs.
Url:
DOI: 10.1016/0002-9149(88)90745-X
Links to Exploration step
ISTEX:11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">An approach to therapy for paroxysmal supraventricular tachycardia</title><author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name><affiliation><mods:affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Sharma, Arjun D" sort="Sharma, Arjun D" uniqKey="Sharma A" first="Arjun D." last="Sharma">Arjun D. Sharma</name><affiliation><mods:affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name><affiliation><mods:affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1016/0002-9149(88)90745-X</idno><idno type="url">https://api-v5.istex.fr/document/11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000153</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000153</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">An approach to therapy for paroxysmal supraventricular tachycardia</title><author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name><affiliation><mods:affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Sharma, Arjun D" sort="Sharma, Arjun D" uniqKey="Sharma A" first="Arjun D." last="Sharma">Arjun D. Sharma</name><affiliation><mods:affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name><affiliation><mods:affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="ISSN">0002-9149</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1987">1987</date><biblScope unit="volume">61</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="A77">A77</biblScope><biblScope unit="page" to="A81">A81</biblScope></imprint><idno type="ISSN">0002-9149</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-9149</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A variety of options are available for managing recurrent paroxysmal supraventricular tachycardia. These options include empirical drug therapy on a trial and error basis, drug therapy based on the results of electrophysiologic testing and nonpharmacologic treatment including operative therapy, catheter ablation and antitachycardia devices. Empirical drug therapy is appropriate when the tachycardia is relatively well tolerated and the patient has access to a medical facility. Therapy guided by electrophysiologic testing is more appropriate for patients with severe symptoms during tachycardia, patients with a potential for more serious arrhythmias such as atrial fibrillation in the Wolff-Parkinson-White syndrome and in patients who have failed to respond to empirical trials of drug therapy. Electrophysiologic testing usually provides information about the precise mechanism responsible for the tachycardia and allows verification of drug efficacy. It is a strict prerequisite for operative, ablative or antitachycardia device therapy. The choice of therapy depends a great deal on local expertise, patient preference and individual considerations. Operative therapy is very successful in patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome and should be given high priority as an option in younger patients facing a lifelong commitment to antiarrhythmic drugs.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>George J. Klein MD</name><affiliations><json:string>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Arjun D. Sharma MD</name><affiliations><json:string>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Raymond Yee MD</name><affiliations><json:string>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</json:string></affiliations></json:item></author><articleId><json:string>8890745X</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>A variety of options are available for managing recurrent paroxysmal supraventricular tachycardia. These options include empirical drug therapy on a trial and error basis, drug therapy based on the results of electrophysiologic testing and nonpharmacologic treatment including operative therapy, catheter ablation and antitachycardia devices. Empirical drug therapy is appropriate when the tachycardia is relatively well tolerated and the patient has access to a medical facility. Therapy guided by electrophysiologic testing is more appropriate for patients with severe symptoms during tachycardia, patients with a potential for more serious arrhythmias such as atrial fibrillation in the Wolff-Parkinson-White syndrome and in patients who have failed to respond to empirical trials of drug therapy. Electrophysiologic testing usually provides information about the precise mechanism responsible for the tachycardia and allows verification of drug efficacy. It is a strict prerequisite for operative, ablative or antitachycardia device therapy. The choice of therapy depends a great deal on local expertise, patient preference and individual considerations. Operative therapy is very successful in patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome and should be given high priority as an option in younger patients facing a lifelong commitment to antiarrhythmic drugs.</abstract><qualityIndicators><score>5.489</score><pdfWordCount>3197</pdfWordCount><pdfCharCount>21603</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>191</abstractWordCount><abstractCharCount>1413</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>An approach to therapy for paroxysmal supraventricular tachycardia</title><pii><json:string>0002-9149(88)90745-X</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>The American Journal of Cardiology</title><language><json:string>unknown</json:string></language><publicationDate>1988</publicationDate><issn><json:string>0002-9149</json:string></issn><pii><json:string>S0002-9149(00)X0751-5</json:string></pii><volume>61</volume><issue>2</issue><pages><first>A77</first><last>A81</last></pages><genre><json:string>journal</json:string></genre><conference><json:item><name>A Symposium: Arrhythmia Therapy-Controversies, Directions and Challenges, Key West, Florida 19870227 19870301</name></json:item></conference></host><categories><wos><json:string>science</json:string><json:string>cardiac & cardiovascular systems</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>cardiovascular system & hematology</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>1987</publicationDate><copyrightDate>1987</copyrightDate><doi><json:string>10.1016/0002-9149(88)90745-X</json:string></doi><id>11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">An approach to therapy for paroxysmal supraventricular tachycardia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1987</date></publicationStmt><notesStmt><note>This study was supported by a grant from the Heart and Stroke Foundation of Ontario (Toronto).</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">An approach to therapy for paroxysmal supraventricular tachycardia</title><author xml:id="author-0000"><persName><forename type="first">George J.</forename><surname>Klein</surname></persName><roleName type="degree">MD</roleName><note type="biography">Address for reprints: George J. Klein, MD, Cardiac Investigation Unit, University Hospital, P.O. Box 5339, Station A, London, Ontario, Canada, N6A 5A5.</note><affiliation>Address for reprints: George J. Klein, MD, Cardiac Investigation Unit, University Hospital, P.O. Box 5339, Station A, London, Ontario, Canada, N6A 5A5.</affiliation><affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Arjun D.</forename><surname>Sharma</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Raymond</forename><surname>Yee</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</affiliation></author><idno type="istex">11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D</idno><idno type="DOI">10.1016/0002-9149(88)90745-X</idno><idno type="PII">0002-9149(88)90745-X</idno><idno type="ArticleID">8890745X</idno></analytic><monogr><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="pISSN">0002-9149</idno><idno type="PII">S0002-9149(00)X0751-5</idno><meeting><addName>A Symposium: Arrhythmia Therapy-Controversies, Directions and Challenges, Key West, Florida</addName><date>19870227</date><date>19870301</date></meeting><imprint><publisher>ELSEVIER</publisher><date type="published" when="1987"></date><biblScope unit="volume">61</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="A77">A77</biblScope><biblScope unit="page" to="A81">A81</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1987</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A variety of options are available for managing recurrent paroxysmal supraventricular tachycardia. These options include empirical drug therapy on a trial and error basis, drug therapy based on the results of electrophysiologic testing and nonpharmacologic treatment including operative therapy, catheter ablation and antitachycardia devices. Empirical drug therapy is appropriate when the tachycardia is relatively well tolerated and the patient has access to a medical facility. Therapy guided by electrophysiologic testing is more appropriate for patients with severe symptoms during tachycardia, patients with a potential for more serious arrhythmias such as atrial fibrillation in the Wolff-Parkinson-White syndrome and in patients who have failed to respond to empirical trials of drug therapy. Electrophysiologic testing usually provides information about the precise mechanism responsible for the tachycardia and allows verification of drug efficacy. It is a strict prerequisite for operative, ablative or antitachycardia device therapy. The choice of therapy depends a great deal on local expertise, patient preference and individual considerations. Operative therapy is very successful in patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome and should be given high priority as an option in younger patients facing a lifelong commitment to antiarrhythmic drugs.</p></abstract></profileDesc><revisionDesc><change when="1987">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>AJC</jid><aid>8890745X</aid><ce:pii>0002-9149(88)90745-X</ce:pii><ce:doi>10.1016/0002-9149(88)90745-X</ce:doi><ce:copyright type="unknown" year="1987"></ce:copyright></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>This study was supported by a grant from the Heart and Stroke Foundation of Ontario (Toronto).</ce:note-para></ce:article-footnote><ce:title>An approach to therapy for paroxysmal supraventricular tachycardia</ce:title><ce:author-group><ce:author><ce:given-name>George J.</ce:given-name><ce:surname>Klein</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Arjun D.</ce:given-name><ce:surname>Sharma</ce:surname><ce:degrees>MD</ce:degrees></ce:author><ce:author><ce:given-name>Raymond</ce:given-name><ce:surname>Yee</ce:surname><ce:degrees>MD</ce:degrees></ce:author><ce:affiliation><ce:textfn>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address for reprints: George J. Klein, MD, Cardiac Investigation Unit, University Hospital, P.O. Box 5339, Station A, London, Ontario, Canada, N6A 5A5.</ce:text></ce:correspondence></ce:author-group><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">A variety of options are available for managing recurrent paroxysmal supraventricular tachycardia. These options include empirical drug therapy on a trial and error basis, drug therapy based on the results of electrophysiologic testing and nonpharmacologic treatment including operative therapy, catheter ablation and antitachycardia devices. Empirical drug therapy is appropriate when the tachycardia is relatively well tolerated and the patient has access to a medical facility. Therapy guided by electrophysiologic testing is more appropriate for patients with severe symptoms during tachycardia, patients with a potential for more serious arrhythmias such as atrial fibrillation in the Wolff-Parkinson-White syndrome and in patients who have failed to respond to empirical trials of drug therapy. Electrophysiologic testing usually provides information about the precise mechanism responsible for the tachycardia and allows verification of drug efficacy. It is a strict prerequisite for operative, ablative or antitachycardia device therapy. The choice of therapy depends a great deal on local expertise, patient preference and individual considerations. Operative therapy is very successful in patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome and should be given high priority as an option in younger patients facing a lifelong commitment to antiarrhythmic drugs.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>An approach to therapy for paroxysmal supraventricular tachycardia</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>An approach to therapy for paroxysmal supraventricular tachycardia</title></titleInfo><name type="personal"><namePart type="given">George J.</namePart><namePart type="family">Klein</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</affiliation><description>Address for reprints: George J. Klein, MD, Cardiac Investigation Unit, University Hospital, P.O. Box 5339, Station A, London, Ontario, Canada, N6A 5A5.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Arjun D.</namePart><namePart type="family">Sharma</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Raymond</namePart><namePart type="family">Yee</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Clinical Electrophysiology Laboratory, University of Western Ontario, London, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1987</dateIssued><copyrightDate encoding="w3cdtf">1987</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">A variety of options are available for managing recurrent paroxysmal supraventricular tachycardia. These options include empirical drug therapy on a trial and error basis, drug therapy based on the results of electrophysiologic testing and nonpharmacologic treatment including operative therapy, catheter ablation and antitachycardia devices. Empirical drug therapy is appropriate when the tachycardia is relatively well tolerated and the patient has access to a medical facility. Therapy guided by electrophysiologic testing is more appropriate for patients with severe symptoms during tachycardia, patients with a potential for more serious arrhythmias such as atrial fibrillation in the Wolff-Parkinson-White syndrome and in patients who have failed to respond to empirical trials of drug therapy. Electrophysiologic testing usually provides information about the precise mechanism responsible for the tachycardia and allows verification of drug efficacy. It is a strict prerequisite for operative, ablative or antitachycardia device therapy. The choice of therapy depends a great deal on local expertise, patient preference and individual considerations. Operative therapy is very successful in patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome and should be given high priority as an option in younger patients facing a lifelong commitment to antiarrhythmic drugs.</abstract><note>This study was supported by a grant from the Heart and Stroke Foundation of Ontario (Toronto).</note><relatedItem type="host"><titleInfo><title>The American Journal of Cardiology</title></titleInfo><titleInfo type="abbreviated"><title>AJC</title></titleInfo><name type="conference"><namePart>A Symposium: Arrhythmia Therapy-Controversies, Directions and Challenges, Key West, Florida</namePart><namePart type="date">19870227</namePart><namePart type="date">19870301</namePart></name><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19880115</dateIssued></originInfo><identifier type="ISSN">0002-9149</identifier><identifier type="PII">S0002-9149(00)X0751-5</identifier><part><date>19880115</date><detail type="issue"><title>A Symposium: Arrhythmia Therapy-Controversies, Directions and Challenges, Key West, Florida</title></detail><detail type="volume"><number>61</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>A1</start><end>A116</end></extent><extent unit="pages"><start>A77</start><end>A81</end></extent></part></relatedItem><identifier type="istex">11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D</identifier><identifier type="DOI">10.1016/0002-9149(88)90745-X</identifier><identifier type="PII">0002-9149(88)90745-X</identifier><identifier type="ArticleID">8890745X</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000153 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000153 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:11F9BA9D9B655E85D9B2BF275FE80D0FEC8D684D
|texte= An approach to therapy for paroxysmal supraventricular tachycardia
}}
| This area was generated with Dilib version V0.6.29. |  |